Research
Hormonal
Caloric restriction prevents or delays the onset of specific aging-related diseases, including cancer, diabetes, cardiovascular disease, and neurodegenerative disorders, in rodents and nonhuman primates.
For humans, strict caloric restriction has been associated with improved biomarkers for diabetes (glucose homeostasis), cardiovascular health (blood pressure, lipid profiles), and potentially reduced risk of neurodegenerative diseases. While it may not guarantee disease prevention, it significantly lowers risk factors associated with these conditions.
ModerateSupportsMEDIUM confidence
In addition to increasing lifespan in rodents, CR has also been shown to delay a wide range of aging-associated diseases, such as cancer, diabetes, atherosclerosis, cardiovascular diseases and neurodegenerative diseases in higher mammals, such as nonhuman primates and humans [13,22-24] (Table 1).
Why this rating
Strong evidence in rodents and primates; human evidence is observational or short-term metabolic trials.
Source
Epigenetic regulation of caloric restriction in aging
Yuanyuan Li et al. · BMC Medicine · 2011
DOI 10.1186/1741-7015-9-98
narrative_reviewCited 191×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Caloric restriction (CR) extends lifespan and delays aging-related diseases in mammals by reversing age-associated aberrant DNA methylation patterns and activating SIRT1-mediated histone deacetylation.Moderate
- Caloric restriction extends lifespan in humans by modulating epigenetic markers, specifically through DNA hypermethylation of the p16INK4a gene promoter and SIRT1-mediated deacetylation.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →